At an industrial hub about an hour outside Copenhagen, engineered yeast cells are fermented to produce semaglutide, the key ingredient in Ozempic and Wegovy, the highly sought-after GLP-1 drugs made by pharmaceutical giant Novo Nordisk. Denmark has a long history as an important contributor to biomedical innovation, including the diabetes treatments for which Novo Nordisk is known. The company, one of the largest employers there, produces half the world’s insulin and was among the first to commercialize its use a hundred years ago.
But Novo Nordisk isn’t the only company in the neighborhood that uses the alchemy of fermentation science to turn microbes into high-demand products. It isn’t even the only Novo.
Just around the corner from the cauldrons of Ozempic is another facility, where three-story fermentation tanks are similarly filled with bacteria and fungi multiplying by the millions in a nutrient-rich broth. The enzymes that get secreted are eventually used by dozens of industries to make everything from food and laundry detergents to biofuel and medicines. The Novo that produces and sells these enzymes is Novonesis.
The similarity in the names isn’t a coincidence. That’s because, until 2000, the two Novos were one company. More than two decades after their corporate breakup, their headquarters, some labs, and production plants remain near one another (and both businesses continue to be controlled by a holding company for the Novo Nordisk Foundation).
“Novo” is Latin for new, and that’s what industrial enzymes were in the 1940s, when the original company introduced its first enzymatic products—one used to clean leather hides before they are tanned, and another for textile desizing, in which amylase breaks down starch agents to prepare fabrics for dyeing. The company was also a pioneer in synthetic biology, launching its first enzyme derived from genetically engineered microorganisms in 1987; lipase is still used today in detergents to help remove stains deposited by a greasy burger or pizza, and some of Novonesis’s biggest customers are Procter & Gamble and Unilever.
Enzymes are proteins that act as catalysts to speed up chemical reactions. For example, they are naturally found in the stomach and help break down food into tiny particles that can be converted into energy. In industrial settings, they are used as a substitute for harsh chemicals, which tend to require higher temperatures and pressure to carry out the necessary reactions. The use of enzymes also prevents unwanted reactions, as each type of enzyme binds only to specific molecules, thus leaving behind less waste than traditional chemicals that could give off hazardous byproducts. And industrial enzymes are a good business: While they comprise a small portion of a manufacturer’s overall cost of goods sold, the switching costs can be high, which gives enzyme suppliers pricing power over their customers. This is especially true for Novonesis, given that it is the dominant player in the oligopolistic niche market.
Another source of strength for Novonesis is its research-and-development strategy. The company has historically spent much more on R&D as a percentage of sales than competitors such as DuPont, DSM, and BASF, and that investment has produced a number of important products and thousands of patents over time. In 2024 alone, Novonesis introduced 45 new products, and 30% of its revenue comes from products launched in the past five years.
Novonesis recently acquired its Danish competitor, Chr. Hansen, which supplies bacteria cultures and probiotics used in products such as yogurts. (The US$12.3 billion deal closed last year.) There are product-level advantages to putting the companies together. For example, adding protein to yogurt changes the texture and taste, but Novonesis can now combine products to better address those issues. Management has said it sees similar synergistic opportunities around food preservation for baked goods.
Revenue growth had been bumpy for Novonesis over the past decade, but recently it has gained positive momentum. Pro-forma sales climbed 5% in 2024 (8% when excluding the negative effects of currencies and acquisitions), and the company projects organic sales growth of 5% to 8% this year. The long-term outlook also looks attractive because there remains a significant opportunity for enzymes to displace chemical additives in industrial production processes. The clearest example is detergents, as producers emphasize products that are more water efficient, enable washing machines to run at lower temperatures, and use fewer harsh chemicals. An expanding middle class in emerging markets could also increase the demand for better household-cleaning products.
It’s also at lower US tariff risk than some other European companies, given that Novonesis has R&D and production facilities in the US, and most of its demand there is fulfilled by local production.
It may not be one of the companies shaking up the splashy market for weight-loss solutions, but Novonesis happens to possess a lot of the traits that investors admire about its better-known sibling: cutting-edge research that allows it to succeed in high-growth markets. For Novonesis, that growth strategy is beginning to bear fruit. ∎